Core Viewpoint - Kaisi China announced the upgrade of the "Marco Polo Program" to version 3.0 during the 8th China International Import Expo, marking a significant milestone in Sino-Italian cooperation and showcasing innovative pharmaceutical products [1] Group 1: Strategic Partnerships - Kaisi China signed a strategic cooperation agreement with JD Health, enabling the full line of respiratory products to be available on the platform, focusing on disease education, online consultations, and smart chronic disease management [2] - Kaisi China upgraded its strategic cooperation with Shanghai Pharmaceutical Cloud Health, allowing its respiratory health products to be integrated into "Yiyao Pharmacy" for comprehensive outpatient services [2] - A memorandum of cooperation was signed with the China Rare Disease Alliance to enhance rare disease management and establish standardized treatment systems [2] Group 2: Product Innovations - In the "CARE" specialty treatment area, Kaisi China showcased its key products for premature infants, including porcine lung surfactant injection and caffeine citrate injection [3] - The "AIR" respiratory health sector introduced a new inhalation powder for asthma patients, providing a new treatment option [3] - Kaisi China presented nine innovative rare disease drugs at the expo, targeting eleven rare diseases, with some being the only treatment options available [3] - The first drug approved for treating wounds related to certain genetic skin disorders was highlighted, benefiting patients in China [3] Group 3: Academic and Professional Development - Kaisi China launched the "Everest Project" to promote high-level academic exchanges and cooperation among top respiratory experts, enhancing medical education and patient management [3]